ChemicalBook CAS DataBase List 1092939-17-7

1092939-17-7

Name	Ruxolitinib phosphate
CAS	1092939-17-7
Molecular Formula	C17H18N6.H3PO4
MDL Number	MFCD18452860
Molecular Weight	404.36
MOL File	1092939-17-7.mol

Synonyms

INC424 INCB 018424 INC 424 phosphate Ruxotinib phosphate Jakafi (ruxolitinib) Ruxolitinib, Phosphate 10-dimethoxyptercarpan INCB018424 (phosphate) INCB-018424 (phosphate) INCB 018424 (phosphate) Ruxolitinib, Phosphate Salt Ruxolitinib phosphate, >=98% Ruxolitinib phosphate(INCB018424) RUXOLITINIB(INCB018424) PHOSPHATE INCB 018424(Ruxolitinib Phosphate) INCB018424;INCB-018424;INCB 018424 Ruxolitinib (INCB-18424) phosphate Ruxolitinib phosphate ISO 9001：2015 REACH RUXOLITINIB PHOSPHATE (INCB018424 PHOSPHATE) Ruxolitinib Phosphate (INC-424, INCB-18424, INCB-018424, Jakafi and Jakavi) INCB018424 PHOSPHATE;INCB 018424 PHOSPHATE;INCB-018424 PHOSPHATE;RUXOLITINIB (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile (βR)-β-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazole-1-propanenitrile Phosphate (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosph (R)-3-(4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate (3R)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphate (betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile phosphate Beta-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(Betar)-1H-pyrazole-1-propanenitrile, phosphate (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphoric acid phosphenoperoxoic acid compound with (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)- 1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile and dihydrogen (1:1:1)

Chemical Properties

Melting point	186-190°C
storage temp.	Refrigerator
solubility	DMSO (Slightly), Methanol (Slightly)
form	Solid
color	White to Off-White
InChI	InChI=1/C17H18N6.H3O4P/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16;1-5(2,3)4/h6,8-12,15H,1-5H2,(H,19,20,21);(H3,1,2,3,4)/t15-;/s3
InChIKey	JFMWPOCYMYGEDM-AVAJOTNLNA-N
SMILES	P(O)(O)(O)=O.[C@@H](C1CCCC1)(N1N=CC(C2N=CN=C3NC=CC=23)=C1)CC#N \|&1:5,r\|

Safety Data

Symbol(GHS)	GHS06,GHS08
Signal word	Danger
Hazard statements	H301-H361-H373
Precautionary statements	P260-P280-P308+P313
HS Code	29331990

Hazard Information

Uses

The phosphate salt of Ruxolitinib (R702000). Ruxolitinib is a selective Janus tyrosine kinase (JAK1 and JAK2) inhibitor used in the treatment of myeloproliferative neoplasms and psoriasis.

Definition

ChEBI: A phosphate salt obtained by reaction ruxolitinib with one equivalent of phosphoric acid. Used for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essent al thrombocythemia myelofibrosis.

Clinical Use

Ruxolitinib phosphate is a potent, selective, ATP competitive inhibitor of tyrosine-protein kinases JAK1 and JAK2 which acts by attenuating cytokine signaling and promotes apoptosis. Ruxolitinib was discovered and developed by Incyte, is marketed under the brand name Jakafi,and is approved for the treatment of patients with myelofibrosis (MF), including primary MF, post-polycythemia vera MP, and post-essential thrombocythemia MF. Ruxolitinib is also undergoing clinical evaluation against a wide variety of cancer indications including metastatic prostate cancer, pancreatic cancer, multiple myeloma, leukemia, non-Hodgkin lymphoma, and breast cancer. Additionally, ruxolitinib is being evaluated for the treatment of psoriasis and thrombocytopenia.

Synthesis

Ruxolitinib contains one chiral center, and three general strategies for its preparation have been reported.165¨C167 These include a racemic synthesis followed by chiral separation or resolution, introduction of the side chain via an aza-Michael addition of the pyrazole fragment to 3- cyclopentylpropiolonitrile and asymmetric hydrogenation of the resulting alkene, and through introduction of the side chain via an organocatalytic, asymmetric aza-Michael addition. The route described herein utilizes the first strategy as this appears to be the largest scale reported.
The synthesis was initiated by SEM protection of commercially available chloropyrrolopyrimidine 201 to provide the protected chloropyrrolopyrimidine 202 in 89% yield. Suzuki coupling of 202 with the pyrazole pinacolatoboronate 203 gave pyrazole 204 in 64% yield. aza-Michael reaction of pyrazole 204 with 3-cyclopentylacrylonitrile 205 was accomplished in the presence of DBU to furnish SEM-protected ruxolitinib 206 in 98% yield as the racemate. The desired enantiomer 207 was isolated via chiral column separation in 93.5% yield and 99.4% ee, on 100 kg scale. Removal of the SEM group was accomplished through a two step process via treatment with lithium tetrafluoroborate and aqueous ammonium hydroxide, ultimately giving rise to ruxolitinib 208 in 84% yield. The phosphate salt was then prepared by treatment with phosphoric acid. Crystallization from MeOH/i-PrOH/n-heptane gave ruxolitinib phosphate (XX) in good overall yield in 99.8% ee. Pyrazole pinacolatoboronate 203 was prepared from pyrazole 209 via iodination with N-iodosuccinimide followed by reaction with trimethyl silyl chloride to give protected iodopyrazaole 210 in high yield. Reaction of 210 with i-PrMgCl to form the corresponding Grignard reagent followed by reaction with isopropylpinacolborane 211 provided Suzuki boronate synthon 203 in 55% yield.

Synthesis_1092939-17-7

storage

Store at -20°C

Questions And Answer

Physical and Chemical Properties

Ruxolitinib, (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3- cyclopentylpropanenitrile phosphate, has a molecular weight of 404.36 kDa. Ruxolitinib is soluble in aqueous solutions at pH 1-8. Ruxolitinib tablets are stable at 20-25°C and tolerate brief exposures to temperatures outside this range, if they stay within 15-30°C.
;
Approval for Use

Ruxolitinib is an oral inhibitor of JAK1 and JAK2, which is approved for the treatment of myeloproliferative neoplasm-associated myelofibrosis, further myeloproliferative neoplasms, polycythemia vera and refractory cancer. In the USA, Canada and EU, ruxolitinib is approved for the treatment of patients with intermediate or high-risk PMF, post-PV MF or post-ET MF. In addition, ruxolitinib recently has been approved for the treatment of patients with PV who have had an inadequate response to or are intolerant of hydroxyurea, based on the results of Phase II and III clinical studies. To date, ruxolitinib has been approved for indications in MF in 83 countries.
;
Side Effects

Common side effects of ruxolitinib treatment include anaemia and thrombocytopenia. The decline of circulating erythrocytes following ruxolitinib treatment could result in part from stimulation of eryptosis, the suicidal erythrocyte death characterized by cell shrinkage and cell membrane scrambling with phosphatidylserine translocation to the cell surface. Cellular mechanisms involved in the execution of eryptosis include oxidative stress, Ca2+ entry with increase of cytosolic Ca2+ activity ([Ca2+]i), ceramide, decline of cytosolic ATP, caspases, stimulated activity of casein kinase 1α, Janus-activated kinase JAK3, protein kinase C, and p38 kinase, as well as impaired activity of AMP activated kinase AMPK, cGMP-dependent protein kinase, PAK2 kinase and sorafenib/sunitinib sensitive kinases.
;

Spectrum Detail

Supplier

CHANGZHOU PHARMACEUTICAL FACTORY

Telephone0519-88821493 18915891730

Websitehttp://www.czpharma.com

Changzhou Yongfeng Biomedicine Co. Ltd.

Telephone 15006117673

Websitehttp://www.yongfengpharm.com

Chongqing Meixing Pharmaceutical Technology Co., Ltd.

Telephone 15023715366

Websitehttps://www.chemicalbook.com/ShowSupplierProductsList612309/0_EN.htm

TargetMol Chemicals Inc.

Telephone021-021-33632979 15002134094

Websitehttps://www.targetmol.cn/

SICHUAN XIELI PHARMACEUTICAL CO.,LTD.

Telephone028-83188610

Websitehttps://www.chemicalbook.com/ShowSupplierProductsList782081/0_EN.htm

Shandong Mingfeng Pharmaceutical and Technology Co. Ltd

Telephone053155551677 15315114555

Websitehttps://www.chemicalbook.com/ShowSupplierProductsList1559998/0_EN.htm

Shanghai Boyle Chemical Co., Ltd.

Telephone

Websitehttp://www.boylechem.com

J & K SCIENTIFIC LTD.

Telephone18210857532 18210857532

Websitehttps://www.jkchemical.com

Chembest Research Laboratories Limited

Telephone021-20908456

Websitehttp://www.BioChemBest.com

Beijing HwrkChemical Technology Co., Ltd

Telephone89508211 18501085097

Websitehttp://www.hwrkchemical.com

BeiJing Hwrk Chemicals Limted

Telephone0757-86329057 18934348241

Websitehttp://www.hwrkchemical.com/

Chemsky（shanghai）International Co.,Ltd.

Telephone021-50135380

Websitehttp://www.shchemsky.com

China DongFan Chemical Co.,LTD

Telephone86-0571-85151182

Websitehttps://www.chemicalbook.com/ShowSupplierProductsList14819/0_EN.htm

Suzhou Ryan Pharmaceutical Technology Co., Ltd.

Telephone0512-68780025 18962125825

Websitehttp://www.ryanchem.com

Chemipanda Bio-Tech Co., Ltd.

Telephone+86-571-85224801; 13588483690

Websitehttp://www.chemipanda.com

Synches Co., Ltd.

Telephone021-53292253

Websitehttp://www.synches.com

Dalian Meilun Biotech Co., Ltd.

Telephone0411-62910999 13889544652

Websitehttp://www.meilunbio.com/

Haoyuan Chemexpress Co., Ltd.

Telephone021-58950125

Websitehttp://gb.chemexpress.com.cn

1of4

Related Products

Send Inquriy